May 10 EpiPen maker Mylan NV said on Wednesday first-quarter profit more than quadrupled, as the maker of generic drugs benefited from strong demand outside the United States.
The company said net income rose to $66.4 million, or 12 cents per share in the first quarter ended March 31, from $13.9 million, or 3 cents per share, a year earlier.
Revenue rose to $2.69 billion from $2.18 billion.
Mylan has been heavily criticized over steep price increases for EpiPen, its life-saving allergy shot, and also for classifying the treatment as a generic rather than a branded product, leading to smaller rebates to state Medicaid programs. (Reporting by Natalie Grover in Bengaluru; Editing by Sai Sachin Ravikumar)
UPDATE 2-Brazil's President Michel Temer charged with taking bribes
BRASILIA, June 26 Brazil's top federal prosecutor charged President Michel Temer with taking multimillion-dollar bribes on Monday in a stinging blow to the unpopular leader and to political stability in Latin America's largest country.
REFILE-Sprint in exclusive talks with Charter, Comcast on wireless deal -WSJ
June 26 Sprint Corp is in exclusive talks with Charter Communications Inc and Comcast Corp to explore a deal that could boost the cable companies' wireless service, The Wall Street Journal reported, citing people familiar with the matter.